Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVOVA-1 vs MC in Advanced Ovarian Cancer
NCT02033616Phase 2
Key facts
- Status
- Unknown
- Start
- Nov 2017
- Primary completion
- Mar 2022
- Countries
- 1
- Sponsor
- AIVITA Biomedical, Inc.
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Drugs
- AV-OVA-1
- Conditions
- ovarian carcinomafallopian tube carcinoma (PFTC)primary peritoneal carcinoma (PPC)
01
Overview
Phase 2, randomised, double-blind trial of AV-OVA-1 in ovarian carcinoma, fallopian tube carcinoma (PFTC) and primary peritoneal carcinoma (PPC) (2 arms), sponsored by AIVITA Biomedical, Inc. Primary endpoint: Overall Survival at 5 years. Status: unknown.
02
Design
2 arms- Study design
- RandomizedDouble-blind
AVOVA-1
Autologous dendritic cells loaded with TAA + GM-CSF
MC
Autologous monocytes + GM-CSF
03
Who it enrols
Patients with Stage III or IV ovarian, fallopian tube, or primary peritoneal cancer who have undergone debulking surgery and chemotherapy, with an ECOG status of 0-1.
04
Endpoints
Primary
Overall Survival
Secondary
Progression-Free Survival
Beyond the preview
Go deeper on NCT02033616.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02033616.